Delivery Order 75N93022D00003-75N93023F00001
Award Date
8/30/23
Potential Completion Date
3/28/27
Potential Value
$10M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Duke University
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Durham, NC 27708, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award to Duke University by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the U.S. Department of Health and Human Services, for a project titled "FEASIBILITY FOR DEVELOPMENT OF A LIPOSOME/LNP DISPLAYING AN HIV ENV TRIMER PROTEIN AND CONTAINING/INCORPORATING AN MRNA." The award, valued at $5,885,384.00, is a delivery order under a larger Preclinical And Translational Vaccine Development For HIV And Other Candidate Agents...
Duke University was awarded a $3,523,482.26 cost-no-fee Delivery Order task order under the Vaccine and Treatment Evaluation Units (VTEU) contract with the National Institutes of Health's National Institute of Allergy and Infectious Diseases. The task order is for the development and implementation of a Phase II vaccine trial for influenza, with a period of performance through March 2021. This task order falls under the broader VTEU program, which supports the evaluation of vaccines and...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, awarded a $19,829,599.29 definitive cost-no-fee contract to Duke University for a Nonhuman Primate Core Humoral Immunology Laboratory to support AIDS vaccine research and development. The contract has a period of performance through March 29, 2025 and does not have a set-aside designation. Duke University's Office of Research Administration Division is the prime contractor for this award, which appears to be...
This is a delivery order contract awarded to Duke University for research and development (R&D) product storage and shipping services. The contract, valued at $4,733,636.00, is under the National Institute of Allergy and Infectious Diseases' (NIAID) "Preclinical And Translational Vaccine Development For HIV And Other Candidate Agents" indefinite delivery, indefinite quantity (IDIQ) vehicle. The contract is not associated with any set-aside designations. Duke University, through its...
This is a federal contract award to Duke University by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), a civilian agency. The award is a $3,190,344.25 delivery order under the Vaccine and Treatment Evaluation Units (VTEU) indefinite delivery, indefinite quantity (IDIQ) contract. The contract is for clinical research and immunization safety assessment services related to vaccines and treatments for infectious diseases. This...
This $7,752,063.96 federal contract award to Duke University's Office of Research Administration Division is a delivery order issued under the Vaccine and Treatment Evaluation Units (VTEU) indefinite delivery, indefinite quantity (IDIQ) contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The award has a period of performance ending on July 12, 2024 and is for vaccine and treatment evaluation work, which aligns with the...
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1,281,164 cost-no-fee delivery order to Duke University's Office of Research Administration Division to conduct a Phase 1 clinical trial on therapeutics against infectious diseases. The order is part of a larger Therapeutics Against Infectious Diseases Phase 1 contract. No set-aside designation was used. Duke University is a private research university...
This is a $6,178,859.14 federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Duke University. The contract is for a "NONHUMAN PRIMATE CORE VIROLOGY LABORATORY FOR AIDS VACCINE RESEARCH AND DEVELOPMENT". This is a definitive, cost-no-fee contract with a period of performance through December 14, 2024. The contract was awarded on December 22, 2017 and does not have a set-aside...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, has awarded a $21,659,151.36 definitive cost-no-fee contract to Duke University to support the "ADVANCED DEVELOPMENT OF A NEUTRALIZING ANTIBODY VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES." This contract, which does not have a set-aside designation, will run through September 18, 2026. Duke University's Office of Research Administration Division will serve as the prime contractor on this...
This is a federal contract award to Duke University by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH). The contract, valued at $10,236,804.91, is a Definitive Contract with a Cost Plus Fixed Fee pricing type. The contract does not have a set-aside designation. The contract is described as "TAS::75 0885::TAS", which likely refers to the task or service area, though the specific details are not provided. The...